Literature DB >> 23360648

Pre-endoscopic Rockall and Blatchford scores to identify which emergency department patients with suspected gastrointestinal bleed do not need endoscopic hemostasis.

Andrew C Meltzer1, Sarah Burnett, Carrie Pinchbeck, Angela L Brown, Tina Choudhri, Kabir Yadav, David E Fleischer, Jesse M Pines.   

Abstract

BACKGROUND: The pre-endoscopic Rockall Score (RS) and the Glasgow-Blatchford Scores (GBS) can help risk stratify patients with upper gastrointestinal bleed who are seen in the Emergency Department (ED). The RS and GBS have yet to be validated in a United States patient population for their ability to discriminate which ED patients with upper gastrointestinal bleed do not need endoscopic hemostasis.
OBJECTIVE: We sought to determine whether patients who received a score of zero on either score (the lowest risk) in the ED still required upper endoscopic hemostasis during hospitalization.
METHODS: Retrospective electronic medical record chart review was performed during a 3-year period (2007-2009) to identify patients with suspected upper gastrointestinal bleed by ED final diagnosis of gastrointestinal hemorrhage and related terms at a single urban academic ED. The RS and GBS were calculated from ED chart abstraction and the hospital records of admitted patients were queried for subsequent endoscopic hemostasis.
RESULTS: Six hundred and ninety patients with gastrointestinal bleed were identified and 86% were admitted to the hospital. One hundred and twenty-two patients had an RS equal to zero; 67 (55%; 95% confidence interval [CI] 46-63%) of these patients were admitted to the hospital and 11 (16%; 95% CI 9-27%) received endoscopic hemostasis. Sixty-three patients had a GBS equal to zero; 15 (24%; 95% CI 15-36%) were admitted to the hospital and 2 (13%; 95% CI 4-38%) received endoscopic hemostasis.
CONCLUSIONS: Some patients who were identified as lowest risk by the GBS or RS still received endoscopic hemostasis during hospital admission. These clinical decision rules may be insufficiently sensitive to predict which patients do not require endoscopic hemostasis.
Copyright © 2013. Published by Elsevier Inc.

Entities:  

Mesh:

Year:  2013        PMID: 23360648     DOI: 10.1016/j.jemermed.2012.11.021

Source DB:  PubMed          Journal:  J Emerg Med        ISSN: 0736-4679            Impact factor:   1.484


  4 in total

1.  Comparison of AIMS65, Glasgow-Blatchford score, and Rockall score in a European series of patients with upper gastrointestinal bleeding: performance when predicting in-hospital and delayed mortality.

Authors:  Juan G Martínez-Cara; Rita Jiménez-Rosales; Margarita Úbeda-Muñoz; Mercedes López de Hierro; Javier de Teresa; Eduardo Redondo-Cerezo
Journal:  United European Gastroenterol J       Date:  2015-09-07       Impact factor: 4.623

2.  Comparison of computed tomography findings with clinical risks factors for endoscopic therapy in upper gastrointestinal bleeding cases.

Authors:  Fumitake Jono; Hiroshi Iida; Koji Fujita; Megumi Kaai; Kenji Kanoshima; Kanji Ohkuma; Takashi Nonaka; Tomonori Ida; Akihiko Kusakabe; Atsushi Nakamura; Shigeru Koyama; Atsushi Nakajima; Masahiko Inamori
Journal:  J Clin Biochem Nutr       Date:  2019-06-28       Impact factor: 3.114

3.  Validity of modified early warning, Glasgow Blatchford, and pre-endoscopic Rockall scores in predicting prognosis of patients presenting to emergency department with upper gastrointestinal bleeding.

Authors:  Seyran Bozkurt; Ataman Köse; Engin Deniz Arslan; Semra Erdoğan; Enver Üçbilek; İbrahim Çevik; Cüneyt Ayrık; Orhan Sezgin
Journal:  Scand J Trauma Resusc Emerg Med       Date:  2015-12-30       Impact factor: 2.953

4.  A Novel Easy-to-Use Prediction Scheme for Upper Gastrointestinal Bleeding: Cologne-WATCH (C-WATCH) Risk Score.

Authors:  Vera Hoffmann; Henrik Neubauer; Julia Heinzler; Anna Smarczyk; Martin Hellmich; Andrea Bowe; Fabian Kuetting; Muenevver Demir; Agnes Pelc; Sigrid Schulte; Ullrich Toex; Dirk Nierhoff; Hans-Michael Steffen
Journal:  Medicine (Baltimore)       Date:  2015-09       Impact factor: 1.817

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.